CCM
NPCE icon

Coldstream Capital Management’s Neuropace NPCE Stock Holding History

Coldstream Capital Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-378
Closed -$4.65K – 2551
2025
Q1 		$4.65K Buy
+378
New +$4.73K ﹤0.01% 2737

Other funds holding NPCE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
KLP
Kent Lake PR Anasco, Puerto Rico $198M AUM 5.21% 1-Year Est. Return

Coldstream Capital Management's NPCE Position: Q2 2025 in Review

Coldstream Capital Management sold out of Neuropace (NPCE) in Q2 2025, closing a stake of 378 shares — an estimated $4.65K sold.

Coldstream Capital Management first reported a position in NPCE in Q1 2025 and held it in 1 quarter. The position peaked at $4.65K in Q1 2025. 98 funds tracked by Wall St. Rank hold NPCE as of Q2 2025.

  • Coldstream Capital Management reported no remaining Neuropace position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 378 Neuropace shares in Q2 2025, an estimated $4.65K.
  • Coldstream Capital Management first reported a position in Neuropace in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Neuropace position peaked at $4.65K in Q1 2025.
  • 98 funds tracked by Wall St. Rank held Neuropace as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.